13-Jan-2025 11:25 PM CST - Business Insider Incyte Stock: Hold Rating Amid Patent Cliff Concerns and Awaited Clinical Milestones JMP Securities analyst Reni Benjamin has reiterated their neutral stance on INCY stock, giving a Hold rating on January ... several factors contributing to the current valuation of Incyte's stock. The company has a potential patent cliff looming with ...
10-Jan-2025 10:40 AM CST - Zacks INCY vs. VRTX: Which Stock Is the Better Value Option? Incyte has a Zacks Rank of #2 (Buy), while Vertex Pharmaceuticals has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that INCY likely has seen a stronger improvement to its earnings outlook than VRTX has recently. But this is just one factor that value investors are interested in.
8-Jan-2025 1:15 AM CST - Business Insider Incyte (INCY) Receives a Hold from Truist Financial In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Hold rating on Incyte (INCY - Research Report), with a
7-Jan-2025 7:36 AM CST - Business Insider Incyte price target raised to $75 from $74 at RBC Capital RBC Capital raised the firm's price target on Incyte (INCY) to $75 from $74 and keeps a Sector Perform rating on the shares as part of a
13-Jan-2025 11:25 PM CST - Business Insider Incyte Stock: Hold Rating Amid Patent Cliff Concerns and Awaited Clinical Milestones JMP Securities analyst Reni Benjamin has reiterated their neutral stance on INCY stock, giving a Hold rating on January ... several factors contributing to the current valuation of Incyte's stock. The company has a potential patent cliff looming with ...
10-Jan-2025 10:40 AM CST - Zacks INCY vs. VRTX: Which Stock Is the Better Value Option? Incyte has a Zacks Rank of #2 (Buy), while Vertex Pharmaceuticals has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that INCY likely has seen a stronger improvement to its earnings outlook than VRTX has recently. But this is just one factor that value investors are interested in.
8-Jan-2025 1:15 AM CST - Business Insider Incyte (INCY) Receives a Hold from Truist Financial In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Hold rating on Incyte (INCY - Research Report), with a
7-Jan-2025 7:36 AM CST - Business Insider Incyte price target raised to $75 from $74 at RBC Capital RBC Capital raised the firm's price target on Incyte (INCY) to $75 from $74 and keeps a Sector Perform rating on the shares as part of a
